Table of Contents

company-logo

Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. It is also developing Olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a treatment for patients with EGFR mutation-positive non-small cell lung cancer; CK-103, a selective and potent small molecule inhibitor of bromodomain and extra-terminal bromodomains; and anti-carbonic anhydrase IX (CAIX) antibody, a fully human preclinical antibody to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has collaboration agreements with TG Therapeutics, Inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

Checkpoint Therapeutics Dividend Announcement

• Checkpoint Therapeutics does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Checkpoint Therapeutics dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Checkpoint Therapeutics Dividend History

Checkpoint Therapeutics Dividend Yield

Checkpoint Therapeutics current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Checkpoint Therapeutics stock? Use our calculator to estimate your expected dividend yield:

Checkpoint Therapeutics Financial Ratios

P/E ratio-3.69
PEG ratio0.06
P/B ratio-13.61
ROE359.97%
Payout ratio0.00%
Current ratio0.29
Quick ratio0.29
Cash Ratio0.26

Checkpoint Therapeutics Dividend FAQ

Does Checkpoint Therapeutics stock pay dividends?
Checkpoint Therapeutics does not currently pay dividends to its shareholders.
Has Checkpoint Therapeutics ever paid a dividend?
No, Checkpoint Therapeutics has no a history of paying dividends to its shareholders. Checkpoint Therapeutics is not known for its dividend payments.
Why doesn't Checkpoint Therapeutics pay dividends?
There are several potential reasons why Checkpoint Therapeutics would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Checkpoint Therapeutics ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Checkpoint Therapeutics has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Checkpoint Therapeutics a dividend aristocrat?
Checkpoint Therapeutics is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Checkpoint Therapeutics a dividend king?
Checkpoint Therapeutics is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Checkpoint Therapeutics a dividend stock?
No, Checkpoint Therapeutics is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Checkpoint Therapeutics stocks?
To buy Checkpoint Therapeutics you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Checkpoint Therapeutics stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.